Jacobs Levy Equity Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.26M	Buy	+86,027	New	+$2M	0.01%	571
2024 Q4	–	Sell	-100,172	Closed	-$932K	–	938
2024 Q3	$932K	Sell	100,172 -75,737	-43%	-$747K	﹤0.01%	732
2024 Q2	$1.64M	Buy	+175,909	New	+$1.59M	0.01%	640
2023 Q1	–	Sell	-190,818	Closed	-$2.82M	–	957
2022 Q4	$2.82M	Sell	190,818 -41,395	-18%	-$723K	0.02%	490
2022 Q3	$4.44M	Buy	+232,213	New	+$5.26M	0.04%	418

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jacobs Levy Equity Management's ARQT Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 86,027 shares worth $2.26M. The stake represents 0.01% of the portfolio and ranks #571 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in ARQT as recently as Q3 2024.

Jacobs Levy Equity Management first reported a position in ARQT in Q3 2022 and has held it in 5 quarters since. The position peaked at $4.44M in Q3 2022. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Jacobs Levy Equity Management held 86,027 shares of Arcutis Biotherapeutics worth $2.26M as of Q2 2026.
Arcutis Biotherapeutics was a new Jacobs Levy Equity Management position in Q2 2026.
Arcutis Biotherapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #571 holding.
Jacobs Levy Equity Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 5 quarters since.
Jacobs Levy Equity Management's Arcutis Biotherapeutics position peaked at $4.44M in Q3 2022.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.